Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 39c; Offers F22 Revenue Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.33), $0.39 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $160 million versus the consensus estimate of $145.75 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2022 revenue of $575 million, versus the consensus of $595 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Franklin Covey (FC) Misses Q3 EPS by 2c, lowers Guidance